1. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Issue 4 (April 2023) Authors: Sweeney, Christopher J; Martin, Andrew J; Stockler, Martin R; Begbie, Stephen; Cheung, Leanna; Chi, Kim N; Chowdhury, Simon; Frydenberg, Mark; Horvath, Lisa G; Joshua, Anthony M; Lawrence, Nicola J; Marx, Gavin; McCaffrey, John; McDermott, Ray; McJannett, Margaret; North, Scott A; Parnis, Francis... Journal: Lancet oncology Issue: Volume 24:Issue 4(2023) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗